This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Align, plaintiffs agree to revised settlement to resolve US antitrust case

( April 24, 2025, 22:32 GMT | Official Statement) -- MLex Summary: Orthodontics company Align Technology and a class of consumers have entered into an amended settlement agreement in response to a California federal judge's order denying their renewed motion for preliminary approval, the plaintiffs told the judge. In an unopposed motion for preliminary approval of their class action settlement, the plaintiffs said the revised settlement is for $31.75 million in cash, "an increase of approximately 15% over the prior cash settlement amount." They said the "settlement (1) is all cash and does not contain any coupon element and thus does not raise any concerns that the settlement may reinforce Align’s alleged monopoly position; and (2) represents a meaningful increase in cash over the prior settlement." Motion for preliminary approval attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections